Michael Landsittel Sells 10,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the completion of the sale, the chief financial officer now owns 47,286 shares of the company’s stock, valued at $4,965,030. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Landsittel also recently made the following trade(s):

• On Thursday, March 28th, Michael Landsittel sold 5,000 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.00, for a total transaction of $475,000.00.
• On Friday, March 15th, Michael Landsittel sold 13,734 shares of Blueprint Medicines stock. The shares were sold at an average price of $87.78, for a total transaction of $1,205,570.52.
• On Thursday, March 7th, Michael Landsittel sold 5,003 shares of Blueprint Medicines stock. The stock was sold at an average price of $90.69, for a total value of $453,722.07.

Blueprint Medicines Stock Up 2.2 %

Shares of Blueprint Medicines stock opened at $108.55 on Wednesday. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $110.93. The company has a 50-day moving average of $92.17 and a 200 day moving average of $81.81. The firm has a market cap of $6.64 billion, a price-to-earnings ratio of -22.57 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm’s revenue was up 85.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.65) earnings per share. As a group, sell-side analysts anticipate that Blueprint Medicines Co. will post -5.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its position in shares of Blueprint Medicines by 63.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 329 shares during the period. Cutler Group LLC CA increased its stake in Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after buying an additional 944 shares in the last quarter. Compass Wealth Management LLC purchased a new position in shares of Blueprint Medicines in the fourth quarter valued at about $69,000. China Universal Asset Management Co. Ltd. grew its position in shares of Blueprint Medicines by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 757 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in Blueprint Medicines by 28.4% during the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 193 shares during the period.

Wall Street Analyst Weigh In

BPMC has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a research report on Thursday, May 2nd. SVB Leerink raised shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and lifted their target price for the stock from $50.00 to $97.00 in a research note on Monday. Wedbush reiterated an “outperform” rating and set a $110.00 price target on shares of Blueprint Medicines in a report on Friday, April 26th. Piper Sandler raised their price target on shares of Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Finally, The Goldman Sachs Group upped their price objective on shares of Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a research note on Monday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines has an average rating of “Hold” and an average price target of $100.31.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.